Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152

View ORCID ProfileRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan Sapkal, Pragya Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma, Sanjay Kumar Rai, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria, Krishna Ella, Balram Bhargava
doi: https://doi.org/10.1101/2020.12.11.20210419
Raches Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raches Ella
  • For correspondence: rachesella@gmail.com
Krishna Mohan Vadrevu
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harsh Jogdand
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Prasad
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddharth Reddy
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vamshi Sarangi
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunda Ganneru
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gajanan Sapkal
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Yadav
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Abraham
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samiran Panda
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nivedita Gupta
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prabhakar Reddy
4Nizams Institute of Medical Sciences, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Verma
5Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Kumar Rai
6All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandramani Singh
7All India Institute of Medical Sciences, Patna, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagar Vivek Redkar
8Redkar Hospital, Dargalim, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Sekhar Gillurkar
9Gillurkar Hospital, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jitendra Singh Kushwaha
10Prakhar Hospital, Kanpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satyajit Mohapatra
11SRM Hospital and Research Centre, Kattankulathur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkat Rao
12Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randeep Guleria
6All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balram Bhargava
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG).

Methods We conducted a double-blind randomized controlled phase 1 clinical trial to evaluate the safety and immunogenicity of BBV152. A total of 375 participants were randomized equally to receive three vaccine formulations (n=100 each) prepared with 3 μg with Algel-IMDG, 6 μg with Algel-IMDG, and 6 μg with Algel, and an Algel only control arm (n=75). Vaccines were administered on a two-dose intramuscular accelerated schedule on day 0 (baseline) and day 14. The primary outcomes were reactogenicity and safety. The secondary outcomes were immunogenicity based on the anti-IgG S1 response (detected with an enzyme-linked immunosorbent assay [ELISA] and wild-type virus neutralization [microneutralization and plaque reduction neutralization assays]). Cell-mediated responses were also evaluated.

Results Reactogenicity was absent in the majority of participants, with mild events. The majority of adverse events were mild and were resolved. One serious adverse event was reported, which was found to be unrelated to vaccination. All three vaccine formulations resulted in robust immune responses comparable to a panel of convalescent serum. No significant differences were observed between the 3-μg and 6-μg Algel-IMDG groups. Neutralizing responses to homologous and heterologous SARS-CoV-2 strains were detected in all vaccinated individuals. Cell-mediated responses were biased to a Th-1 phenotype.

Conclusions BBV152 induced binding and neutralising antibody responses and with the inclusion of the Algel-IMDG adjuvant, this is the first inactivated SARS-CoV-2 vaccine that has been reported to induce a Th1-biased response. Vaccine induced neutralizing antibody titers were reported with two divergent SARS-CoV-2 strains. BBV152 is stored between 2°C and 8°C, which is compatible with all national immunization program cold chain requirements. Both Algel-IMDG formulations were selected for the phase 2 immunogenicity trials. Further efficacy trials are underway.

Clinicaltrials.gov: NCT04471519

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04471519

Funding Statement

This study was funded by Bharat Biotech.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the National Regulatory Authority (India) and the respective Ethics Committees and was conducted in compliance with all International Council for Harmonization (ICH) Good Clinical Practice guidelines. Full names and affiliations of each Ethics Committee members were not disclosed to the Sponsor. Ethics Committees Approval Site Name, Reference Number Nizams Institute of Medical Science, Hyderabad, Telangana, ECR/303/INST/AP/2013/RR-19 All India Institute of Medical Science, New DelhiECR/547/INST/DL/2014/RR-17 PGIMS, Rohtak, HaryanaECR/293/Inst/HR/2013/RR-19 All India Institute of Medical Science, PatnaECR/1387/INST/BR/2020 Redkar Hospital/Research Centre, GoaECR/902/INST/GA/2018 IMS/SUM Hospital, OdishaECR/627/INST/OR/2014/RR-17 Jeevan Rekha Hospital, Belgaum, KarnatakaECR/1242/INST/KA/2019 Gillukar Multispeciality Hospital, NagpurECR/1374/INST/MH/2020 Rana Hospital and Trauma Center, Gorakhpur, Uttar PradeshECR/1332/INST/UP/2020 Prakhar Hospital, Kanpur, Utter PradeshECR/1017/INST/UP/2017 SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu, ECR/431/INST/TL/2013/RR-19

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This is an interim report of an ongoing clinical trial. This report was prespecified in the protocol.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 15, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152
Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan Sapkal, Pragya Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma, Sanjay Kumar Rai, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria, Krishna Ella, Balram Bhargava
medRxiv 2020.12.11.20210419; doi: https://doi.org/10.1101/2020.12.11.20210419
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152
Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan Sapkal, Pragya Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma, Sanjay Kumar Rai, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria, Krishna Ella, Balram Bhargava
medRxiv 2020.12.11.20210419; doi: https://doi.org/10.1101/2020.12.11.20210419

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1426)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (586)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5019)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)